Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) Expected to Announce Earnings of -$0.06 Per Share

Equities analysts predict that Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) will report earnings per share of ($0.06) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Zomedica Pharmaceuticals Corp (NYSEAMERICAN)’s earnings. Zomedica Pharmaceuticals Corp (NYSEAMERICAN) reported earnings of ($0.04) per share during the same quarter last year, which would suggest a negative year over year growth rate of 50%. The business is expected to report its next quarterly earnings report on Thursday, August 8th.

On average, analysts expect that Zomedica Pharmaceuticals Corp (NYSEAMERICAN) will report full-year earnings of ($0.26) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the business will post earnings of ($0.11) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that cover Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) last released its quarterly earnings results on Friday, May 10th. The company reported ($0.12) earnings per share for the quarter.

Separately, HC Wainwright reaffirmed a “buy” rating on shares of Zomedica Pharmaceuticals in a report on Wednesday, June 5th.

Shares of ZOM remained flat at $$0.25 during mid-day trading on Friday. The stock had a trading volume of 99,888 shares, compared to its average volume of 521,749. The stock has a 50 day moving average price of $0.26. The stock has a market cap of $27.33 million, a P/E ratio of -1.41 and a beta of 0.49. Zomedica Pharmaceuticals Corp has a 52 week low of $0.20 and a 52 week high of $2.40.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 13.3% during the 4th quarter. Geode Capital Management LLC now owns 136,655 shares of the company’s stock worth $168,000 after purchasing an additional 16,065 shares in the last quarter. BlackRock Inc. grew its stake in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 2.3% during the 4th quarter. BlackRock Inc. now owns 1,767,342 shares of the company’s stock worth $2,173,000 after purchasing an additional 40,244 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 56.5% during the 4th quarter. Rhumbline Advisers now owns 46,410 shares of the company’s stock worth $57,000 after purchasing an additional 16,750 shares in the last quarter. 14.64% of the stock is currently owned by institutional investors.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Company Profile

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.

Further Reading: How Do Investors Open a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.